CTOs on the Move

We launched Atara Biotherapeutics in August 2012 to help patients combat cancer, kidney disease and other illnesses. Our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors as well as allogeneic, or third-party derived, antigen-specific T-cells, to change the course of disease progression. Our goal is to help patients such as Atara Ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. We aim to empower patients to fight their illnesses with better treatment options. We are a three year-old clinical stage publicly traded (NASDAQ exchange symbol ATRA) biopharmaceutical company focused ...

We launched Atara Biotherapeutics in August 2012 to help patients combat cancer, kidney disease and other illnesses. Our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors as well as allogeneic, or third-party derived, antigen-specific T-cells, to change the course of disease progression. Our goal is to help patients such as Atara Ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. We aim to empower patients to fight their illnesses with better treatment options. We are a three year-old clinical stage publicly traded (NASDAQ exchange symbol ATRA) biopharmaceutical company focused on developing innovative novel therapies for patients with debilitating diseases and serious unmet medical needs. We are co-located by design in Westlake Village, CA (northwest LA) and South San Francisco, CA. Atara Bio two groups of product candidate programs include molecularly targeted product biologics and allogeneic, or third-party derived, antigen-specific T-cells, a type of white blood cell product candidates. Our initial T-cell product candidates target viral- or cancer-specific antigens and are designed to harness the body’s immune system to counteract specific viral infections and cancers. Our most advanced T-cell product candidate, EBV-CTL, in in Phase 2 clinical trials with an FDA breakthrough designation. Our other T-cell product candidates include CMV-CTL and WT1-CTL. Our molecularly targeted product candidate is STM 434. Atara Bio commenced a Phase 1 clinical study of STM 434 for ovarian cancer and other solid tumors in 2014.

More>>

<<Less